San Jose, CA, October 16, 2010 --(PR.com
)-- AnaSpec is pleased to announce the release of two HAT (histone acetyltransferase) fluorimetric kits adding in our growing list of epigenetics research products.
The SensoLyte p300 Assay Kit provides a convenient assay for the screening of enzyme inhibitors and for continuous measurement of p300 activity. For added convenience, this kit includes two peptide substrates: histone H3 (1-21) peptide and non-histone p53 peptide (368-386). After incubation with acetyl CoA and the substrate, the p300 enzyme generates acetylated H3 or p53 peptide and CoASH. The thiol groups of CoASH can be detected with a fluorogenic reagent at excitation/emission=389nm/513nm.
The SensoLyte HAT (pCAF) Assay Kit provides a convenient assay for screening of enzyme inhibitors and for continuous measurement of pCAF activity. After incubation with acetyl CoA and histone H3 (1-21) peptide, the pCAF enzyme generates acetylated H3 peptide and CoASH. The detection of the CoASH thiol group is the same as above.
Histone acetyltransferases (HATs) enzymes regulate the acetylation of histones and non-histone proteins.1, 2 The acetylation of the e-amino groups of lysine residues present at histone tails correlates largely with transcriptional activation, but it is also involved in DNA replication, DNA repair and protein–protein interactions.3 HATs play major roles in the control of cell fate and misregulation is implicated in the development of some human tumors.4,5 HAT p300 is a transcriptional coactivator that acetylates core histones facilitating chromatin decondensation and recruiting basic RNA polymerase machinery.6 Many non-histone proteins, such as p53, STATs, and alpha interferon receptor, also serve as substrates for p300.7 The p300/CBP-associated factor (pCAF) acetylates specific lysines on the N-terminal tails of histones H3 and H4.
1. Roth, SY. et al. Annu Rev Biochem. 70, 81 (2001).
2. Glozak, MA. et al. Gene. 363, 15 (2005).
3. Turner, BM. Bioessays 22, 836 (2000).
4. Timmermann, S. et al. Cell Mol Life Sci. 58, 728 (2001).
5. Iyer, NG. et al. Oncogene. 23, 4225 (2004).
6. Chan, HM. et al. J Cell Sci. 114, 2363 (2001).
7. Grossman, SR. Eur J Biochem. 268, 2773 (2001).
AnaSpec is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and antibodies.
AnaSpec recently joined forces with Eurogentec to provide an even broader spectrum of products and services to serve the worldwide life science community.
For more information visit www.anaspec.com
Eurogentec is a leading global supplier of innovative reagents, kits, specialty products and custom services to scientists in the life science, biotechnology, pharmaceutical and diagnostic markets. Eurogentec provides a wide range of expertize in small- and large-scale DNA, RNA, PCR and qPCR kits, peptide synthesis and antibody supply for research applications. Our ISO13485:2003-certified manufacturing facilities in Belgium provides a wide range of high value oligonucleotide-based components for diagnostic and therapeutic applications. Eurogentec’s Belgium manufacturing facility is complemented by additional production facilities in North America and Japan. Eurogentec is also an experienced Contract Manufacturing Organization (CMO) for Biopharmaceuticals, operating a full-service, state-of-the-art GMP facility in Belgium.
Eurogentec is a privately held company headquartered in Liège, Belgium, with subsidiaries in North America, France, Germany, the UK, the Netherlands and Switzerland and has additional production facilities in North America, Japan and Singapore. Eurogentec employs 400+ people globally.
For more information visit www.eurogentec.com